公司资料
FEMASYS 股价、新闻与催化剂
- 股票代码:
- FEMY
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.10 USD (-2.78%)
收盘价
最后更新: 2026年10月1日
22.4M USD
市值
股价为何变动
截至 2026年10月1日，FEMY 下跌 2.78%，收于 $2.10。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Women's Health Medical Device Company
Femasys develops office-based products for reproductive health. Its portfolio addresses permanent contraception, infertility treatment, and diagnostic evaluation of the uterus and fallopian tubes.
FemBloc Permanent Contraception
FemBloc is a non-surgical permanent birth-control system delivered through the fallopian tubes in a physician's office. The product is designed to avoid surgical incisions, general anesthesia, and implanted metal devices.
FINALE Pivotal Program
The FINALE study is the final stage of the U.S. pivotal clinical program for FemBloc. The trial is intended to provide the effectiveness and safety evidence needed for a future FDA submission.
FemaSeed Fertility Treatment
FemaSeed delivers sperm directly into a selected fallopian tube, closer to the site of fertilization than standard intrauterine insemination. It is positioned as an office-based option before more invasive assisted-reproduction procedures.
Diagnostic Product Portfolio
FemVue and FemCath products help physicians evaluate fallopian-tube patency and the uterine cavity. These commercial devices provide an established channel with obstetricians, gynecologists, and fertility specialists.
未来催化剂
- Completion of the pivotal FINALE study of FemBloc to support a future U.S. regulatory submission.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。